Browse the evidence

Dose-dependent effects were more prominent for MASH resolution than fibrosis improvement.

Practitioners should consider the dosage of anti-diabetic agents when aiming for MASH resolution.

GLP-1 receptor agonists can induce psychiatric side effects such as increased impulsivity, dysphoria, and aggression.

Physicians should be cautious of potential psychiatric side effects when prescribing GLP-1 RAs.

The psychiatric side effects resolved with medication cessation.

Discontinuation of GLP-1 RAs may alleviate associated psychiatric symptoms.

There may be a relationship between GLP-1 receptor agonists and mood.

Further investigation is warranted to understand the mood-related effects of GLP-1 RAs.

Metabolomic subtypes have shown potential in guiding treatment selection for obesity.

Practitioners can consider metabolomic profiles to tailor obesity treatments.

GLP-1 agonists influence various obesity-related processes including food intake regulation, insulin resistance, and inflammation.

Understanding these mechanisms can help practitioners tailor obesity treatments more effectively.

Co-stimulation of GLP-1 with other receptors like GIP and glucagon may provide additional therapeutic benefits.

Practitioners should consider combination therapies involving GLP-1 for enhanced weight loss effects.

Metformin was widely found to be weight-neutral with minimal effects on muscle mass.

Practitioners can consider Metformin as a weight-neutral option with minimal impact on muscle mass.

Metabolic dysfunction associated steatohepatitis (MASH) is a leading cause of chronic liver disease worldwide.

Healthcare providers should recognize MASH as a significant health concern.

Prolonged and unreasonable use of GLP-1 agonists may lead to undesirable effects.

Healthcare providers should monitor patients for potential adverse effects when using GLP-1 agonists long-term.

MASLD presents extrahepatic manifestations such as cardiovascular disease, type 2 diabetes, and chronic kidney disease.

Clinicians should consider the broader health implications of MASLD beyond liver health.

The review discusses emerging therapeutic strategies for MASLD and its associated comorbidities.

Practitioners should stay informed about new treatment options for MASLD and its comorbidities.

GLP-1 RA initiation was associated with a reduced incidence of all-cause mortality post RYGB (1.2% vs. 3.9%) with a hazard ratio of 0.497.

Practitioners may consider GLP-1 RAs to potentially improve survival rates in patients post RYGB.

GLP-1 RAs influence blood pressure through mechanisms such as sympathetic nervous modulation, vasodilation, and diuretic effects.

Understanding these mechanisms can help in tailoring hypertension treatments.

The blood pressure-lowering effects of GLP-1 RAs are often independent of weight loss or glucose control.

GLP-1 RAs may be beneficial for hypertension management even in patients not focused on weight loss or glucose control.

Integrating pharmacological, minimally invasive, and genetic strategies may enhance long-term weight management and metabolic outcomes.

Combining different treatment modalities may lead to better results for patients with obesity.

Obesity is a leading cause of morbidity and mortality with health consequences that crosscut most medical specialties.

Healthcare providers should recognize the widespread impact of obesity on health.

There are many impediments to comprehensive obesity care despite the emergence of effective therapies.

Clinicians should be aware of and address barriers to effective obesity treatment.

Pharmacological classes of metabolic drugs have unexpected and often beneficial effects on cardiovascular outcomes.

Consider the use of metabolic drugs in managing cardiovascular health.

Obesity, sarcopenia, and heart failure with preserved ejection fraction (HFpEF) are interconnected through the adipokine axis.

Understanding the link between these conditions can guide treatment strategies.

A maladaptive adipokine milieu is associated with endothelial dysfunction, myocardial stiffening, and muscle atrophy in HFpEF.

Recognizing this cycle can inform targeted interventions.

Emerging translational applications include diagnostic and prognostic adipokine signatures and therapeutic impacts of GLP-1 receptor agonists.

These applications could enhance clinical practice in managing HFpEF.

Current pharmacological treatments aim to restore energy balance by targeting disrupted pathways.

Practitioners should be aware of pharmacological options that target energy balance in obesity management.

BMI is not sufficient to define obesity; pathophysiology and the impact of mechanical, metabolic, and psychological complications must be considered.

Practitioners should consider multiple factors beyond BMI when assessing obesity.